Clomipramine

Modify Date: 2024-01-03 21:50:50

Clomipramine Structure
Clomipramine structure
Common Name Clomipramine
CAS Number 303-49-1 Molecular Weight 314.852
Density 1.1±0.1 g/cm3 Boiling Point 434.2±45.0 °C at 760 mmHg
Molecular Formula C19H23ClN2 Melting Point N/A
MSDS N/A Flash Point 216.4±28.7 °C

 Use of Clomipramine


Clomipramine (Chlorimipramine) is a potent 5-HT reuptake blocker with the IC50 value of 1.5 nM. Clomipramine is a tricyclic antidepressant that can be used for the research of depression and obsessive compulsive disorder (OCD)[1].

 Names

Name clomipramine
Synonym More Synonyms

 Clomipramine Biological Activity

Description Clomipramine (Chlorimipramine) is a potent 5-HT reuptake blocker with the IC50 value of 1.5 nM. Clomipramine is a tricyclic antidepressant that can be used for the research of depression and obsessive compulsive disorder (OCD)[1].
Related Catalog
In Vitro Clomipramine can inhibit reuptake of both noradrenaline and 5-HT, although Clomipramine inhibits 5-HT reuptake more strongly than it inhibits noradrenaline reuptake[1]. The antidepressant Clomipramine inhibits both venom AChE as well as human serum BChE in a concentration-dependent manner but has no effect on AChE in the rat brain striatum[2]. Clomipramine interferes with the autophagic flux and severely compromises the viability of tumorigenic cells upon cytotoxic stress[3]. Clomipramine reduces autophagy in neuronal primary cultures. Clomipramine (1 and 5 µM) negatively regulates neuronal autophagic pathway in primary cultured cells[3]. Western Blot Analysis[3] Cell Line: Primary cortical neurons Concentration: 1 and 5 µM Incubation Time: 12, 24 and 48 hours Result: Enhanced the LC3-I conversion to LC3-II in a concentration-dependent manner at all analyzed time points.
In Vivo Clomipramine (5-20 mg/kg; i.p) elicits significant hyperglycemia in mice. Clomipramine induces hyperglycemia in mice by blocking the 5-HT2B and/or 5-HT2C receptors, which results in facilitation of adrenaline release. In mice, Clomipramine reduces immobility in the forced swimming test, which is the behavioral model for antidepressants. Clomipramine also inhibits the OCD animal model, marble burying behavior in mice[1]. Clomipramine (20 mg/kg) decreases autophagic flux in murine tissues[3]. Animal Model: C57BL/6 J mice (6 weeks of age and 22 to 25 g)[3] Dosage: 20 mg/kg Administration: Treated intraperitoneally for 21 days Result: Both LC3-II and p62 were significantly increased in the liver of Clomipramine treated mice compared to vehicle treated ones.
References

[1]. Yumi Sugimoto, et al. The tricyclic antidepressant Clomipramine increases plasma glucose levels of mice. J Pharmacol Sci. 2003 Sep;93(1):74-9.

[2]. Mushtaq Ahmed, et al. Comparative study of the inhibitory effect of antidepressants on cholinesterase activity in Bungarus sindanus (krait) venom, human serum and rat striatum. J Enzyme Inhib Med Chem. 2008 Dec;23(6):912-7.

[3]. Federica Cavaliere,The tricyclic antidepressant Clomipramine inhibits neuronal autophagic flux. Sci Rep. 2019 Mar 19;9(1):4881.

 Chemical & Physical Properties

Density 1.1±0.1 g/cm3
Boiling Point 434.2±45.0 °C at 760 mmHg
Molecular Formula C19H23ClN2
Molecular Weight 314.852
Flash Point 216.4±28.7 °C
Exact Mass 314.154968
PSA 6.48000
LogP 5.39
Vapour Pressure 0.0±1.0 mmHg at 25°C
Index of Refraction 1.582
Water Solubility H2O: 25 mg/mL

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
HN9050000
CHEMICAL NAME :
5H-Dibenz(b,f)azepine, 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-
CAS REGISTRY NUMBER :
303-49-1
BEILSTEIN REFERENCE NO. :
1323477
LAST UPDATED :
199612
DATA ITEMS CITED :
16
MOLECULAR FORMULA :
C19-H23-Cl-N2
MOLECULAR WEIGHT :
314.89
WISWESSER LINE NOTATION :
T C676 BN&T&J B3N1&1 EG

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
357 ug/kg
TOXIC EFFECTS :
Gastrointestinal - nausea or vomiting
REFERENCE :
JCPYDR Journal of Clinical Pyschopharmacology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1981- Volume(issue)/page/year: 2,215,1982
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
10 mg/kg/5D-I
TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 1,406,1971
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
30 mg/kg
TOXIC EFFECTS :
Behavioral - coma Gastrointestinal - changes in structure or function of endocrine pancreas Gastrointestinal - decreased motility or constipation
REFERENCE :
JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 32,425,1994
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
3400 ug/kg/47M-I
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Cardiac - cardiomyopathy including infarction
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 3,698,1972
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
613 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973- Volume(issue)/page/year: 24,335,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
149 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973- Volume(issue)/page/year: 24,335,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
380 mg/kg
TOXIC EFFECTS :
Behavioral - wakefulness Behavioral - changes in motor activity (specific assay)
REFERENCE :
GWXXBX German Offenlegungsschrift Patent Document. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #2618152
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
150 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 21,448,1978
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
27 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
APSXAS Acta Pharmaceutica Suecica. (Apotekarsocieteten-Farmacevtiska Foereningen, Box 1136, S-111, 81 Stockholm, Sweden) V.1- 1964- Volume(issue)/page/year: 13,485,1976 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2857 ug/kg
SEX/DURATION :
male 4 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - impotence
REFERENCE :
CJPSDF Canadian Journal of Psychiatry. (Keith Health Care Communications, 289 Rutherford Rd. South, Suite 11, Brampton, ON L6W 3R9, Canada) Volume(issue)/page/year: 27,148,1982
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
50 mg/kg
SEX/DURATION :
female 38-47 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system
REFERENCE :
TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 24(1),42A,1981
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
6850 mg/kg
SEX/DURATION :
female 1-39 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - other neonatal measures or effects
REFERENCE :
JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 29,479,1991
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
420 mg/kg
SEX/DURATION :
lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - physical
REFERENCE :
PSCHDL Psychopharmacology (Berlin). (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.47- 1976- Volume(issue)/page/year: 56,93,1978
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
400 mg/kg
SEX/DURATION :
female 20 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - physical
REFERENCE :
PSCHDL Psychopharmacology (Berlin). (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.47- 1976- Volume(issue)/page/year: 56,93,1978
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
66 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
REFERENCE :
PSCHDL Psychopharmacology (Berlin). (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.47- 1976- Volume(issue)/page/year: 79,236,1983
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
150 mg/kg
SEX/DURATION :
female 7-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
REFERENCE :
JNGSE8 Journal of Neural Transmission. General Section. (Springer-Verlag, Postfach 367, A-1011, Vienna, Austria) V.78- 1989- Volume(issue)/page/year: 90,113,1992

 Safety Information

Hazard Codes Xn: Harmful;
Risk Phrases R20/21/22
Safety Phrases S36
WGK Germany 3
RTECS HN9055000
HS Code 2933990090

 Synthetic Route

~83%

Clomipramine Structure

Clomipramine

CAS#:303-49-1

Literature: Tetrahedron Letters, , vol. 51, # 43 p. 5690 - 5693

 Customs

HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Synonyms

3-Chloroimipramine
Chlorimipramine
3-Chloro-10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine
5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-
5H-Dibenz[b,f]azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl-
MFCD00069234
Clomipramine
3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine
5-(g-Dimethylaminopropyl)-3-chloroiminodibenzyl
3-Chloro-10,11-dihydro-5-(3-dimethylaminopropyl)-5H-dibenz[b,f]azepine
3-chloro-10,11-dihydro-N,N-dimethyl-5H-Dibenz(b,f)azepine-5-propanamine
Hydiphen
Clomipramina
10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5H-dibenz(b,f)azepine
3-Chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine
3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine
Monochlorimipramine
ANAFRANIL
3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine
chloripramine
EINECS 206-144-2
Chlomipramine
Anafranil base
Top Suppliers:I want be here



Get all suppliers and price by the below link:

Clomipramine suppliers

Clomipramine price